A New Day Dawns For Avastin
Executive Summary
The launch of Mvasi will be the first biosimilar version of Avastin in the US, a huge blockbuster for Roche approved for multiple cancer indications. Scrip looks at the development and commercial history of Avastin since its FDA approval in 2004.
You may also be interested in...
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.
Regeneron Oncology Setback Delivered By US FDA Crackdown On Accelerated Approval
The company received two complete response letters from the US FDA for the CD20xCD3 bispecific antibody odronextamab due to clinical trial requirements for accelerated approval.